Advantage Alpha Capital Partners LP Acquires Shares of 5,772 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Advantage Alpha Capital Partners LP acquired a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 5,772 shares of the specialty pharmaceutical company’s stock, valued at approximately $344,000.

Other large investors also recently bought and sold shares of the company. Global Alpha Capital Management Ltd. raised its stake in ANI Pharmaceuticals by 1.8% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock valued at $32,005,000 after purchasing an additional 9,500 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new position in shares of ANI Pharmaceuticals in the second quarter worth about $600,000. Susquehanna Fundamental Investments LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth about $228,000. Boston Partners acquired a new position in ANI Pharmaceuticals during the first quarter worth about $606,000. Finally, Thompson Siegel & Walmsley LLC raised its holdings in ANI Pharmaceuticals by 17.6% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock valued at $13,731,000 after acquiring an additional 34,416 shares during the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ANIP has been the topic of several recent research reports. Piper Sandler began coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price on the stock. Truist Financial boosted their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Finally, Raymond James raised their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.33.

ANI Pharmaceuticals Stock Down 1.3 %

Shares of NASDAQ:ANIP opened at $57.86 on Wednesday. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -105.20 and a beta of 0.71. ANI Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $70.81. The business has a 50-day moving average price of $58.36 and a 200 day moving average price of $60.83. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals’s revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.05 earnings per share. Sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.